Adlaon, Kyle .

HRN: 26-25-86  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/19/2024
AMPICILLIN 250MG (VIAL)
11/19/2024
11/26/2024
IVTT
135
Q6h
Neonatal Sepsis
Waiting Final Action 
11/19/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
11/19/2024
11/26/2024
IVTT
40mg
Q24h
T/C Neonatal Sepsis
Waiting Final Action 
11/22/2024
CEFOTAXIME 500MG (VIAL)
11/22/2024
11/28/2024
IV
180 Mg
Q8H
Neonatal Sepsis
Waiting Final Action 
11/22/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
11/22/2024
11/28/2024
IV
5 Mg
Q8H
Neonatal Sepsis
Waiting Final Action 
11/22/2024
GENTAMICIN 40MG/ML, 2ML (AMP)
11/22/2024
11/28/2024
IV
13.5 Mg
OD
Neonatal Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: